ArticlePloS one2026
CMCL-DDI: Pharmacophore-aware cross-view contrastive learning for drug-drug interaction prediction.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prediction of potential drug-drug interactions (DDIs) is vital for ensuring medication safety and efficacy. Existing graph-based methods typically focus on molecular structures but often overlook the complementary semantic information embedded in SMILES (Simplified Molecular Input Line Entry System) representations. To address this gap, we propose CMCL-DDI, a Cross-view Mutual Contrastive Learning framework that jointly leverages pharmacophore-aware molecular graphs and SMILES sequences. Specifically, we encode pharmacophore-based subgraphs to capture functional molecular features and aggregate them into expressive graph-level embeddings. In parallel, SMILES sequences are encoded to preserve sequential drug characteristics. A contrastive learning strategy aligns both views in a shared latent space, facilitating mutual representation enhancement. Furthermore, we design a cross-attention fusion module to integrate heterogeneous features, enabling robust and interpretable DDI prediction. Extensive experiments on benchmark datasets demonstrate that CMCL-DDI consistently outperforms state-of-the-art models, highlighting the effectiveness of cross-view representation learning for DDI prediction. The source codes are available at https://github.com/95LY/CMCL-DDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.